fann的个人主页 - 老虎社区

fann

fann

暂无个人介绍

IP属地：未知

125关注

12粉丝

0主题

0勋章

2021-11-28

v

2 Leading Growth Stocks to Buy in 2021 and Beyond

2021-11-24

yes

XPeng shares rose nearly 12% in early trading

2021-11-13

d

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-10

h

Wall Street losses end streak of record highs as inflation worry weighs on market

2021-09-26

ss

Intel Starts Construction of Two Arizona Computer Chip Factories

2021-09-24

s

EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3585997214465926,"uuid":"3585997214465926","gmtCreate":1622903189881,"gmtModify":1627956052914,"name":"fann","pinyin":"fann","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":125,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600939962,"gmtCreate":1638029748530,"gmtModify":1638029748620,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"v","listText":"v","text":"v","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600939962","repostId":"2186389343","repostType":4,"repost":{"id":"2186389343","pubTimestamp":1637974214,"share":"https://www.laohu8.com/m/news/2186389343?lang=&edition=full","pubTime":"2021-11-27 08:50","market":"us","language":"en","title":"2 Leading Growth Stocks to Buy in 2021 and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2186389343","media":"Motley Fool","summary":"These two stocks could be ready to soar next year.","content":"<p>Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that could be the market darlings of 2022 and beyond.</p>\n<p>Two trends that will surely lead to big returns are the emerging digital economy and demand for computer peripherals from the growing adoption of remote work. Here's why <b>Logitech International</b> (NASDAQ:LOGI) and <b>Coinbase Global</b> (NASDAQ:COIN) are well positioned to tackle these opportunities and deliver major gains for investors.</p>\n<h2>Logitech: A leading brand of computer peripherals</h2>\n<p>Logitech has seen growing demand in recent years from a few different trends. One is the increasing popularity of gaming, particularly esports. CEO Bracken Darrell previously said, \"Gaming will grow to become the biggest collection of sports in the world one day from both a participant and a spectator standpoint.\" The company is also benefiting as more businesses shift to a hybrid workforce, allowing employees to split time between working at home or at the office. Both opportunities are boosting sales of Logitech's mice, keyboards, webcams, and headsets.</p>\n<p>The share price has fallen this year as a result of difficult year-over-year comparisons with calendar 2020 when the stay-at-home environment drove sales through the roof.&nbsp;However, the gaming peripherals market is expected to roughly double in size to $8.7 billion by 2027, according to Research and Markets.&nbsp;That's a strong tailwind for Logitech's gaming business, which generated revenue of $1.4 billion over the last four quarters.</p>\n<p>The number of remote workers is also expected to continue increasing over the next few years. <b>Gartner</b> estimates 53% of the U.S. workforce will be working remotely in 2022&nbsp;with similar trends across Europe, India, and China.</p>\n<p>Logitech is gaining market share across most of its product categories, but supply chain challenges could pressure near-term growth. The tough growth comparisons with last year and the near-term headwinds are giving investors a great opportunity to buy the stock at a forward price-to-earnings multiple of 18.4.&nbsp;These valuation levels should lay the foundation for market-beating returns.</p>\n<h2>Coinbase: A leading cryptocurrency exchange</h2>\n<p>Coinbase is one of the largest exchanges for buying and selling cryptocurrency. It has over 73 million verified users across more than 100 countries. It is popular for its easy-to-use interface that includes helpful educational features to help new users get up to speed on the burgeoning cryptoeconomy, but it may win over millions more users as the digital economy goes mainstream.</p>\n<p>The stock started trading in April through a direct listing and is currently down 18% from its opening price on April 14, but it's probably only a matter of time until shares bounce back. The company is growing very fast with assets on the platform rising from $36 billion in the third quarter of 2020 to $255 billion in the same period this year. The surge in demand pushed net profit up to $406 million in the latest quarter.</p>\n<p>Investors should keep in mind management is not interested in maximizing profits right now, instead focusing on investments in new products and services to attract more users to the platform. Profits could decline during periods of soft trading volume, but Coinbase should continue to see an upward trend for its user base over the next several years, and that's the most important progress to think about.</p>\n<p>It's estimated that up to 200 million people have used <b>Bitcoin</b>,&nbsp;but with the most popular cryptocurrency still gaining adoption worldwide, especially in developing countries, the number of people using it could reach one billion in the next five years, according to some analysts. This makes Coinbase's 7.4 million monthly transacting users look minuscule by comparison.</p>\n<p>The opportunity is clear, but Coinbase currently trades at a relatively modest price-to-earnings ratio of 28 for a growth stock, which could look very cheap in another 10 years.&nbsp;This is one of the top cryptocurrency stocks to consider in this booming market.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Leading Growth Stocks to Buy in 2021 and Beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Leading Growth Stocks to Buy in 2021 and Beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-27 08:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LOGI":"罗技","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186389343","content_text":"Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that could be the market darlings of 2022 and beyond.\nTwo trends that will surely lead to big returns are the emerging digital economy and demand for computer peripherals from the growing adoption of remote work. Here's why Logitech International (NASDAQ:LOGI) and Coinbase Global (NASDAQ:COIN) are well positioned to tackle these opportunities and deliver major gains for investors.\nLogitech: A leading brand of computer peripherals\nLogitech has seen growing demand in recent years from a few different trends. One is the increasing popularity of gaming, particularly esports. CEO Bracken Darrell previously said, \"Gaming will grow to become the biggest collection of sports in the world one day from both a participant and a spectator standpoint.\" The company is also benefiting as more businesses shift to a hybrid workforce, allowing employees to split time between working at home or at the office. Both opportunities are boosting sales of Logitech's mice, keyboards, webcams, and headsets.\nThe share price has fallen this year as a result of difficult year-over-year comparisons with calendar 2020 when the stay-at-home environment drove sales through the roof. However, the gaming peripherals market is expected to roughly double in size to $8.7 billion by 2027, according to Research and Markets. That's a strong tailwind for Logitech's gaming business, which generated revenue of $1.4 billion over the last four quarters.\nThe number of remote workers is also expected to continue increasing over the next few years. Gartner estimates 53% of the U.S. workforce will be working remotely in 2022 with similar trends across Europe, India, and China.\nLogitech is gaining market share across most of its product categories, but supply chain challenges could pressure near-term growth. The tough growth comparisons with last year and the near-term headwinds are giving investors a great opportunity to buy the stock at a forward price-to-earnings multiple of 18.4. These valuation levels should lay the foundation for market-beating returns.\nCoinbase: A leading cryptocurrency exchange\nCoinbase is one of the largest exchanges for buying and selling cryptocurrency. It has over 73 million verified users across more than 100 countries. It is popular for its easy-to-use interface that includes helpful educational features to help new users get up to speed on the burgeoning cryptoeconomy, but it may win over millions more users as the digital economy goes mainstream.\nThe stock started trading in April through a direct listing and is currently down 18% from its opening price on April 14, but it's probably only a matter of time until shares bounce back. The company is growing very fast with assets on the platform rising from $36 billion in the third quarter of 2020 to $255 billion in the same period this year. The surge in demand pushed net profit up to $406 million in the latest quarter.\nInvestors should keep in mind management is not interested in maximizing profits right now, instead focusing on investments in new products and services to attract more users to the platform. Profits could decline during periods of soft trading volume, but Coinbase should continue to see an upward trend for its user base over the next several years, and that's the most important progress to think about.\nIt's estimated that up to 200 million people have used Bitcoin, but with the most popular cryptocurrency still gaining adoption worldwide, especially in developing countries, the number of people using it could reach one billion in the next five years, according to some analysts. This makes Coinbase's 7.4 million monthly transacting users look minuscule by comparison.\nThe opportunity is clear, but Coinbase currently trades at a relatively modest price-to-earnings ratio of 28 for a growth stock, which could look very cheap in another 10 years. This is one of the top cryptocurrency stocks to consider in this booming market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875729976,"gmtCreate":1637697368889,"gmtModify":1637697369016,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875729976","repostId":"1117658681","repostType":4,"repost":{"id":"1117658681","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637681053,"share":"https://www.laohu8.com/m/news/1117658681?lang=&edition=full","pubTime":"2021-11-23 23:24","market":"us","language":"en","title":"XPeng shares rose nearly 12% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1117658681","media":"Tiger Newspress","summary":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported ","content":"<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares rose nearly 12% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares rose nearly 12% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-23 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09868":"小鹏汽车-W","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117658681","content_text":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.\nRevenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.\nGross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873030150,"gmtCreate":1636789657540,"gmtModify":1636789657680,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873030150","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847285132,"gmtCreate":1636524401929,"gmtModify":1636524758936,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847285132","repostId":"1188205095","repostType":4,"repost":{"id":"1188205095","pubTimestamp":1636498317,"share":"https://www.laohu8.com/m/news/1188205095?lang=&edition=full","pubTime":"2021-11-10 06:51","market":"us","language":"en","title":"Wall Street losses end streak of record highs as inflation worry weighs on market","url":"https://stock-news.laohu8.com/highlight/detail?id=1188205095","media":"Reuters","summary":"(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record clos","content":"<p>(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.</p>\n<p>All three major U.S. stock indexes lost ground, marking the conclusion of an eight-session streak of all-time closing highs set by the S&amp;P 500 and the Nasdaq.</p>\n<p>After such a run, and in the absence of market-moving catalysts, market participants appeared primed to take profits.</p>\n<p>\"We've had an incredible run, so letting some air out of the balloon is perfectly normal,\" said Ryan Detrick, chief market strategist at LPL Financial in Charlotte, North Carolina.</p>\n<p>\"It's a reminder that stocks can’t go up every day,\" Detrick added. \"We’re seeing some oversold weakness today, nothing overly concerning.\"</p>\n<p>The Labor Department's producer prices (PPI) report showed inflation continues to gather heat as ongoing goods and labor supply challenges send price growth further beyond the U.S. Federal Reserve's average annual 2% inflation target.</p>\n<p>Wednesday's CPI report will be scrutinized for clues regarding the extent to which producer prices are being passed along to the consumer, whose spending represents about 70% of the U.S. economy.</p>\n<p>The Dow Jones Industrial Average(.DJI)fell 112.24 points, or 0.31%, to 36,319.98, the S&amp;P 500(.SPX)lost 16.45 points, or 0.35%, to 4,685.25 and the Nasdaq Composite(.IXIC)dropped 95.81 points, or 0.6%, to 15,886.54.</p>\n<p>Five of the 11 major sectors of the S&amp;P 500 ended the session red, with consumer discretionary(.SPLRCD)shedding 1.4%, the largest percentage drop. Utilities(.SPLRCU)led the gainers, advancing 0.4%.</p>\n<p>The finish line for third-quarter earnings season is in sight, with 445 of the companies in the S&amp;P 500 having reported. Of those, 81% have beat consensus, according to Refinitiv.</p>\n<p>General Electric Co(GE.N)surged 2.6% following the 129-year-old industrial conglomerate's announcement that it would split into three separate public companies to simplify its business.read more</p>\n<p>Tesla Inc(TSLA.O)plunged 12.0%, weighing on the consumer discretionary sector(.SPLRCD)and extending its losses after Chief Executive Elon Musk's Twitter poll proposing to sell a tenth of his holdings garnered a 57.9% vote in favor of the sale. This raised questions as to whether Musk violated a settlement with the U.S. Securities and Exchange Commission (SEC).read more</p>\n<p>Online retail stock-trading app Robinhood Markets Inc(HOOD.O)reported a security breach affecting about 5 million customers, sending its shares sliding dropped 3.4%.read more</p>\n<p>On the plus side, upbeat quarterly results sent video game maker Zynga Inc(ZNGA.O)jumping 9.4% and shares of homebuilder D.R. Horton(DHI.N)up 5.2%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.13-to-1 ratio; on Nasdaq, a 1.40-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 34 new 52-week highs and two new lows; the Nasdaq Composite recorded 120 new highs and 73 new lows.</p>\n<p>Volume on U.S. exchanges was 11.02 billion shares, compared with the 10.76 billion average over the last 20 trading days.</p>\n<p><a href=\"https://laohu8.com/NW/2182089540\" target=\"_blank\">NIO Inc. Reports Unaudited Third Quarter 2021 Financial Results</a></p>\n<p>NIO Inc. (NIO) reported mixed financial results for&nbsp;Q3 FY 2021. The company posted a loss per&nbsp;share of RMB 1.82 ($0.28), more than twice as large as the loss per share analysts expected. Revenue, however, beat expectations, rising 116.6% year over year (YOY). NIO's vehicle deliveries, which were reported at the beginning of October, exceeded analysts' forecasts. The company's shares fell more than 2% in post-market trading. Over the past year, NIO's shares have provided a&nbsp;total return&nbsp;of -7.7%, well below the S&amp;P 500's total return of 32.0%.</p>\n<p><a href=\"https://laohu8.com/NW/2182898260\" target=\"_blank\">Coinbase Stock Sinks 10% Following Q3 Revenue Miss, Analyst Highlights Worsening Take Rate</a></p>\n<p>Coinbase (NASDAQ: COIN) shares were trading more than 10% lower after-hours, following the company’s Q3 results, with revenue coming in at $1.31 billion ($1.1 billion in transaction revenue and $145 million in Subscription and services revenue), below the consensus estimate of $1.56 billion. Quarterly EPS of $1.62 was better than the consensus estimate of $1.57. Verified Users grew to 73 million in Q3 and retail Monthly Transacting Users (MTUs) were 7.4 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182089825\" target=\"_blank\">DoorDash Stock Rips Higher on Earnings, Plan to Acquire Wolt for ~$8B</a></p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> (NYSE: DASH) shares surged 12% after hours Tuesday following earnings and news the company will acquire Finland-based Wolt Enterprises OY, a leading local commerce platform across 23 countries, in an all-stock transaction valued approximately at €7 billion (U.S. $8.09 billion).</p>\n<p><a href=\"https://laohu8.com/NW/2182089829\" target=\"_blank\">Upstart Stock Plunges 22% Despite Q3 Beat</a></p>\n<p>Upstart Holdings (NASDAQ: UPST) shares were trading around 22% lower after-hours, despite the company’s reported Q3 beat, with EPS coming in at $0.60, better than the consensus estimate of $0.35. Quarterly revenue grew 250% to $228.5 million, beating the consensus estimate of $214.9 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182086726\" target=\"_blank\">Sports-Focused Streamer FuboTV Smashes Subscriber Goal In Third Quarter</a></p>\n<p>FuboTV lost 74 cents a share on sales of $156.7 million in the third quarter. Wall Street had predicted a loss of 61 cents a share on revenue of $143.5 million, FactSet said.On an adjusted basis, FuboTV lost 59 cents a share, compared with a loss of $1.08 a share in the year-earlier period.</p>\n<p><a href=\"https://laohu8.com/NW/2182864180\" target=\"_blank\">Unity Software Beats Third-Quarter Targets, Buys Weta Digital</a></p>\n<p>Video game design and animation software maker<b>Unity Software</b> late Tuesday crushed Wall Street's sales target for the third quarter and reported a smaller loss than expected. Unity stock was in record high territory ahead of the earnings report.</p>\n<p>The San Francisco-based company lost an adjusted 6 cents a share on sales of $286.3 million in the September quarter. Analysts expected Unity to lose 7 cents a share on sales of $266.5 million, according to FactSet. In the year-earlier period, Unity lost 9 cents a share on sales of $200.8 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182865910\" target=\"_blank\">PubMatic Announces Third Quarter 2021 Financial Results</a></p>\n<li>Revenue in the third quarter of 2021 was $58.1 million, an increase of 54% over $37.8 million in the same period of 2020;&nbsp;GAAP net income was $13.5 million, or $0.24 per diluted share in the third quarter, an increase over net income of $6.2 million, or $0.10 per diluted share in the same period of 2020.</li>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street losses end streak of record highs as inflation worry weighs on market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street losses end streak of record highs as inflation worry weighs on market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 06:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.\nAll three ...</p>\n\n<a href=\"https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188205095","content_text":"(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.\nAll three major U.S. stock indexes lost ground, marking the conclusion of an eight-session streak of all-time closing highs set by the S&P 500 and the Nasdaq.\nAfter such a run, and in the absence of market-moving catalysts, market participants appeared primed to take profits.\n\"We've had an incredible run, so letting some air out of the balloon is perfectly normal,\" said Ryan Detrick, chief market strategist at LPL Financial in Charlotte, North Carolina.\n\"It's a reminder that stocks can’t go up every day,\" Detrick added. \"We’re seeing some oversold weakness today, nothing overly concerning.\"\nThe Labor Department's producer prices (PPI) report showed inflation continues to gather heat as ongoing goods and labor supply challenges send price growth further beyond the U.S. Federal Reserve's average annual 2% inflation target.\nWednesday's CPI report will be scrutinized for clues regarding the extent to which producer prices are being passed along to the consumer, whose spending represents about 70% of the U.S. economy.\nThe Dow Jones Industrial Average(.DJI)fell 112.24 points, or 0.31%, to 36,319.98, the S&P 500(.SPX)lost 16.45 points, or 0.35%, to 4,685.25 and the Nasdaq Composite(.IXIC)dropped 95.81 points, or 0.6%, to 15,886.54.\nFive of the 11 major sectors of the S&P 500 ended the session red, with consumer discretionary(.SPLRCD)shedding 1.4%, the largest percentage drop. Utilities(.SPLRCU)led the gainers, advancing 0.4%.\nThe finish line for third-quarter earnings season is in sight, with 445 of the companies in the S&P 500 having reported. Of those, 81% have beat consensus, according to Refinitiv.\nGeneral Electric Co(GE.N)surged 2.6% following the 129-year-old industrial conglomerate's announcement that it would split into three separate public companies to simplify its business.read more\nTesla Inc(TSLA.O)plunged 12.0%, weighing on the consumer discretionary sector(.SPLRCD)and extending its losses after Chief Executive Elon Musk's Twitter poll proposing to sell a tenth of his holdings garnered a 57.9% vote in favor of the sale. This raised questions as to whether Musk violated a settlement with the U.S. Securities and Exchange Commission (SEC).read more\nOnline retail stock-trading app Robinhood Markets Inc(HOOD.O)reported a security breach affecting about 5 million customers, sending its shares sliding dropped 3.4%.read more\nOn the plus side, upbeat quarterly results sent video game maker Zynga Inc(ZNGA.O)jumping 9.4% and shares of homebuilder D.R. Horton(DHI.N)up 5.2%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.13-to-1 ratio; on Nasdaq, a 1.40-to-1 ratio favored decliners.\nThe S&P 500 posted 34 new 52-week highs and two new lows; the Nasdaq Composite recorded 120 new highs and 73 new lows.\nVolume on U.S. exchanges was 11.02 billion shares, compared with the 10.76 billion average over the last 20 trading days.\nNIO Inc. Reports Unaudited Third Quarter 2021 Financial Results\nNIO Inc. (NIO) reported mixed financial results for Q3 FY 2021. The company posted a loss per share of RMB 1.82 ($0.28), more than twice as large as the loss per share analysts expected. Revenue, however, beat expectations, rising 116.6% year over year (YOY). NIO's vehicle deliveries, which were reported at the beginning of October, exceeded analysts' forecasts. The company's shares fell more than 2% in post-market trading. Over the past year, NIO's shares have provided a total return of -7.7%, well below the S&P 500's total return of 32.0%.\nCoinbase Stock Sinks 10% Following Q3 Revenue Miss, Analyst Highlights Worsening Take Rate\nCoinbase (NASDAQ: COIN) shares were trading more than 10% lower after-hours, following the company’s Q3 results, with revenue coming in at $1.31 billion ($1.1 billion in transaction revenue and $145 million in Subscription and services revenue), below the consensus estimate of $1.56 billion. Quarterly EPS of $1.62 was better than the consensus estimate of $1.57. Verified Users grew to 73 million in Q3 and retail Monthly Transacting Users (MTUs) were 7.4 million.\nDoorDash Stock Rips Higher on Earnings, Plan to Acquire Wolt for ~$8B\nDoorDash, Inc. (NYSE: DASH) shares surged 12% after hours Tuesday following earnings and news the company will acquire Finland-based Wolt Enterprises OY, a leading local commerce platform across 23 countries, in an all-stock transaction valued approximately at €7 billion (U.S. $8.09 billion).\nUpstart Stock Plunges 22% Despite Q3 Beat\nUpstart Holdings (NASDAQ: UPST) shares were trading around 22% lower after-hours, despite the company’s reported Q3 beat, with EPS coming in at $0.60, better than the consensus estimate of $0.35. Quarterly revenue grew 250% to $228.5 million, beating the consensus estimate of $214.9 million.\nSports-Focused Streamer FuboTV Smashes Subscriber Goal In Third Quarter\nFuboTV lost 74 cents a share on sales of $156.7 million in the third quarter. Wall Street had predicted a loss of 61 cents a share on revenue of $143.5 million, FactSet said.On an adjusted basis, FuboTV lost 59 cents a share, compared with a loss of $1.08 a share in the year-earlier period.\nUnity Software Beats Third-Quarter Targets, Buys Weta Digital\nVideo game design and animation software makerUnity Software late Tuesday crushed Wall Street's sales target for the third quarter and reported a smaller loss than expected. Unity stock was in record high territory ahead of the earnings report.\nThe San Francisco-based company lost an adjusted 6 cents a share on sales of $286.3 million in the September quarter. Analysts expected Unity to lose 7 cents a share on sales of $266.5 million, according to FactSet. In the year-earlier period, Unity lost 9 cents a share on sales of $200.8 million.\nPubMatic Announces Third Quarter 2021 Financial Results\nRevenue in the third quarter of 2021 was $58.1 million, an increase of 54% over $37.8 million in the same period of 2020; GAAP net income was $13.5 million, or $0.24 per diluted share in the third quarter, an increase over net income of $6.2 million, or $0.10 per diluted share in the same period of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868517299,"gmtCreate":1632671469211,"gmtModify":1632798663240,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ss","listText":"ss","text":"ss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868517299","repostId":"1142057327","repostType":4,"repost":{"id":"1142057327","pubTimestamp":1632643246,"share":"https://www.laohu8.com/m/news/1142057327?lang=&edition=full","pubTime":"2021-09-26 16:00","market":"us","language":"en","title":"Intel Starts Construction of Two Arizona Computer Chip Factories","url":"https://stock-news.laohu8.com/highlight/detail?id=1142057327","media":"The street","summary":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to","content":"<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p>\n<p>Intel&nbsp;(<b>INTC</b>) -Get Intel Corporation (INTC) Report&nbsp;on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help&nbsp;alleviate the severe shortage of semiconductors in the U.S.</p>\n<p>The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p>\n<p>Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p>\n<p>“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p>\n<p>\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p>\n<p>Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p>\n<p>Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p>\n<p>The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p>\n<p>Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Starts Construction of Two Arizona Computer Chip Factories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Starts Construction of Two Arizona Computer Chip Factories\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-26 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories><strong>The street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC)...</p>\n\n<a href=\"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142057327","content_text":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.\nThe Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.\nIntel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.\n“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.\n\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.\nShares of Intel on Friday traded 0.18% higher to $54.32 after hours.\nGelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.\nThe two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.\nIntel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.","news_type":1},"isVote":1,"tweetType":1,"viewCount":353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861838061,"gmtCreate":1632479579653,"gmtModify":1632719680697,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"s","listText":"s","text":"s","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861838061","repostId":"1147407851","repostType":4,"repost":{"id":"1147407851","pubTimestamp":1632476902,"share":"https://www.laohu8.com/m/news/1147407851?lang=&edition=full","pubTime":"2021-09-24 17:48","market":"us","language":"en","title":"EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407851","media":"zerohedge","summary":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing","content":"<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p>\n<p>Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p>\n<p>In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p>\n<p>But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p>\n<p>Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p>\n<p>The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p>\n<p>Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p>\n<p></p>\n<p></p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until...</p>\n\n<a href=\"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147407851","content_text":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until early October,Reuters reportedThursday.\nReuters pointed out thatthe upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabsin the EU.\nIn an opinion issued earlier this month that was republished by the EMA,the European Center for Disease Prevention and Control- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -said there was no \"urgent need\" to administer booster dosesto fully vaccinated individuals in the general population.\nBut it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever\nRegardless of whatever the bloc decides,it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.\nThe latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.\nStill, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":868517299,"gmtCreate":1632671469211,"gmtModify":1632798663240,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"ss","listText":"ss","text":"ss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868517299","repostId":"1142057327","repostType":4,"repost":{"id":"1142057327","pubTimestamp":1632643246,"share":"https://www.laohu8.com/m/news/1142057327?lang=&edition=full","pubTime":"2021-09-26 16:00","market":"us","language":"en","title":"Intel Starts Construction of Two Arizona Computer Chip Factories","url":"https://stock-news.laohu8.com/highlight/detail?id=1142057327","media":"The street","summary":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to","content":"<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p>\n<p>Intel&nbsp;(<b>INTC</b>) -Get Intel Corporation (INTC) Report&nbsp;on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help&nbsp;alleviate the severe shortage of semiconductors in the U.S.</p>\n<p>The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p>\n<p>Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p>\n<p>“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p>\n<p>\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p>\n<p>Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p>\n<p>Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p>\n<p>The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p>\n<p>Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Starts Construction of Two Arizona Computer Chip Factories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Starts Construction of Two Arizona Computer Chip Factories\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-26 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories><strong>The street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC)...</p>\n\n<a href=\"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142057327","content_text":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.\nThe Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.\nIntel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.\n“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.\n\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.\nShares of Intel on Friday traded 0.18% higher to $54.32 after hours.\nGelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.\nThe two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.\nIntel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.","news_type":1},"isVote":1,"tweetType":1,"viewCount":353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875729976,"gmtCreate":1637697368889,"gmtModify":1637697369016,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875729976","repostId":"1117658681","repostType":4,"repost":{"id":"1117658681","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637681053,"share":"https://www.laohu8.com/m/news/1117658681?lang=&edition=full","pubTime":"2021-11-23 23:24","market":"us","language":"en","title":"XPeng shares rose nearly 12% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1117658681","media":"Tiger Newspress","summary":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported ","content":"<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares rose nearly 12% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares rose nearly 12% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-23 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XPeng&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;early&nbsp;trading&nbsp;after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p>\n<p>Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p>\n<p>Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09868":"小鹏汽车-W","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117658681","content_text":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.\nRevenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.\nGross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873030150,"gmtCreate":1636789657540,"gmtModify":1636789657680,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873030150","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861838061,"gmtCreate":1632479579653,"gmtModify":1632719680697,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"s","listText":"s","text":"s","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861838061","repostId":"1147407851","repostType":4,"repost":{"id":"1147407851","pubTimestamp":1632476902,"share":"https://www.laohu8.com/m/news/1147407851?lang=&edition=full","pubTime":"2021-09-24 17:48","market":"us","language":"en","title":"EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407851","media":"zerohedge","summary":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing","content":"<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p>\n<p>Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p>\n<p>In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p>\n<p>But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p>\n<p>Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p>\n<p>The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p>\n<p>Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p>\n<p></p>\n<p></p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-24 17:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until...</p>\n\n<a href=\"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147407851","content_text":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until early October,Reuters reportedThursday.\nReuters pointed out thatthe upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabsin the EU.\nIn an opinion issued earlier this month that was republished by the EMA,the European Center for Disease Prevention and Control- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -said there was no \"urgent need\" to administer booster dosesto fully vaccinated individuals in the general population.\nBut it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever\nRegardless of whatever the bloc decides,it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.\nThe latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.\nStill, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.","news_type":1},"isVote":1,"tweetType":1,"viewCount":395,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847285132,"gmtCreate":1636524401929,"gmtModify":1636524758936,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847285132","repostId":"1188205095","repostType":4,"repost":{"id":"1188205095","pubTimestamp":1636498317,"share":"https://www.laohu8.com/m/news/1188205095?lang=&edition=full","pubTime":"2021-11-10 06:51","market":"us","language":"en","title":"Wall Street losses end streak of record highs as inflation worry weighs on market","url":"https://stock-news.laohu8.com/highlight/detail?id=1188205095","media":"Reuters","summary":"(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record clos","content":"<p>(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.</p>\n<p>All three major U.S. stock indexes lost ground, marking the conclusion of an eight-session streak of all-time closing highs set by the S&amp;P 500 and the Nasdaq.</p>\n<p>After such a run, and in the absence of market-moving catalysts, market participants appeared primed to take profits.</p>\n<p>\"We've had an incredible run, so letting some air out of the balloon is perfectly normal,\" said Ryan Detrick, chief market strategist at LPL Financial in Charlotte, North Carolina.</p>\n<p>\"It's a reminder that stocks can’t go up every day,\" Detrick added. \"We’re seeing some oversold weakness today, nothing overly concerning.\"</p>\n<p>The Labor Department's producer prices (PPI) report showed inflation continues to gather heat as ongoing goods and labor supply challenges send price growth further beyond the U.S. Federal Reserve's average annual 2% inflation target.</p>\n<p>Wednesday's CPI report will be scrutinized for clues regarding the extent to which producer prices are being passed along to the consumer, whose spending represents about 70% of the U.S. economy.</p>\n<p>The Dow Jones Industrial Average(.DJI)fell 112.24 points, or 0.31%, to 36,319.98, the S&amp;P 500(.SPX)lost 16.45 points, or 0.35%, to 4,685.25 and the Nasdaq Composite(.IXIC)dropped 95.81 points, or 0.6%, to 15,886.54.</p>\n<p>Five of the 11 major sectors of the S&amp;P 500 ended the session red, with consumer discretionary(.SPLRCD)shedding 1.4%, the largest percentage drop. Utilities(.SPLRCU)led the gainers, advancing 0.4%.</p>\n<p>The finish line for third-quarter earnings season is in sight, with 445 of the companies in the S&amp;P 500 having reported. Of those, 81% have beat consensus, according to Refinitiv.</p>\n<p>General Electric Co(GE.N)surged 2.6% following the 129-year-old industrial conglomerate's announcement that it would split into three separate public companies to simplify its business.read more</p>\n<p>Tesla Inc(TSLA.O)plunged 12.0%, weighing on the consumer discretionary sector(.SPLRCD)and extending its losses after Chief Executive Elon Musk's Twitter poll proposing to sell a tenth of his holdings garnered a 57.9% vote in favor of the sale. This raised questions as to whether Musk violated a settlement with the U.S. Securities and Exchange Commission (SEC).read more</p>\n<p>Online retail stock-trading app Robinhood Markets Inc(HOOD.O)reported a security breach affecting about 5 million customers, sending its shares sliding dropped 3.4%.read more</p>\n<p>On the plus side, upbeat quarterly results sent video game maker Zynga Inc(ZNGA.O)jumping 9.4% and shares of homebuilder D.R. Horton(DHI.N)up 5.2%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.13-to-1 ratio; on Nasdaq, a 1.40-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 34 new 52-week highs and two new lows; the Nasdaq Composite recorded 120 new highs and 73 new lows.</p>\n<p>Volume on U.S. exchanges was 11.02 billion shares, compared with the 10.76 billion average over the last 20 trading days.</p>\n<p><a href=\"https://laohu8.com/NW/2182089540\" target=\"_blank\">NIO Inc. Reports Unaudited Third Quarter 2021 Financial Results</a></p>\n<p>NIO Inc. (NIO) reported mixed financial results for&nbsp;Q3 FY 2021. The company posted a loss per&nbsp;share of RMB 1.82 ($0.28), more than twice as large as the loss per share analysts expected. Revenue, however, beat expectations, rising 116.6% year over year (YOY). NIO's vehicle deliveries, which were reported at the beginning of October, exceeded analysts' forecasts. The company's shares fell more than 2% in post-market trading. Over the past year, NIO's shares have provided a&nbsp;total return&nbsp;of -7.7%, well below the S&amp;P 500's total return of 32.0%.</p>\n<p><a href=\"https://laohu8.com/NW/2182898260\" target=\"_blank\">Coinbase Stock Sinks 10% Following Q3 Revenue Miss, Analyst Highlights Worsening Take Rate</a></p>\n<p>Coinbase (NASDAQ: COIN) shares were trading more than 10% lower after-hours, following the company’s Q3 results, with revenue coming in at $1.31 billion ($1.1 billion in transaction revenue and $145 million in Subscription and services revenue), below the consensus estimate of $1.56 billion. Quarterly EPS of $1.62 was better than the consensus estimate of $1.57. Verified Users grew to 73 million in Q3 and retail Monthly Transacting Users (MTUs) were 7.4 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182089825\" target=\"_blank\">DoorDash Stock Rips Higher on Earnings, Plan to Acquire Wolt for ~$8B</a></p>\n<p><a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a> (NYSE: DASH) shares surged 12% after hours Tuesday following earnings and news the company will acquire Finland-based Wolt Enterprises OY, a leading local commerce platform across 23 countries, in an all-stock transaction valued approximately at €7 billion (U.S. $8.09 billion).</p>\n<p><a href=\"https://laohu8.com/NW/2182089829\" target=\"_blank\">Upstart Stock Plunges 22% Despite Q3 Beat</a></p>\n<p>Upstart Holdings (NASDAQ: UPST) shares were trading around 22% lower after-hours, despite the company’s reported Q3 beat, with EPS coming in at $0.60, better than the consensus estimate of $0.35. Quarterly revenue grew 250% to $228.5 million, beating the consensus estimate of $214.9 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182086726\" target=\"_blank\">Sports-Focused Streamer FuboTV Smashes Subscriber Goal In Third Quarter</a></p>\n<p>FuboTV lost 74 cents a share on sales of $156.7 million in the third quarter. Wall Street had predicted a loss of 61 cents a share on revenue of $143.5 million, FactSet said.On an adjusted basis, FuboTV lost 59 cents a share, compared with a loss of $1.08 a share in the year-earlier period.</p>\n<p><a href=\"https://laohu8.com/NW/2182864180\" target=\"_blank\">Unity Software Beats Third-Quarter Targets, Buys Weta Digital</a></p>\n<p>Video game design and animation software maker<b>Unity Software</b> late Tuesday crushed Wall Street's sales target for the third quarter and reported a smaller loss than expected. Unity stock was in record high territory ahead of the earnings report.</p>\n<p>The San Francisco-based company lost an adjusted 6 cents a share on sales of $286.3 million in the September quarter. Analysts expected Unity to lose 7 cents a share on sales of $266.5 million, according to FactSet. In the year-earlier period, Unity lost 9 cents a share on sales of $200.8 million.</p>\n<p><a href=\"https://laohu8.com/NW/2182865910\" target=\"_blank\">PubMatic Announces Third Quarter 2021 Financial Results</a></p>\n<li>Revenue in the third quarter of 2021 was $58.1 million, an increase of 54% over $37.8 million in the same period of 2020;&nbsp;GAAP net income was $13.5 million, or $0.24 per diluted share in the third quarter, an increase over net income of $6.2 million, or $0.10 per diluted share in the same period of 2020.</li>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street losses end streak of record highs as inflation worry weighs on market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street losses end streak of record highs as inflation worry weighs on market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 06:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.\nAll three ...</p>\n\n<a href=\"https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/wall-street-losses-end-streak-record-highs-inflation-worry-weighs-market-2021-11-09/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188205095","content_text":"(Reuters) - Wall Street closed lower on Tuesday, ending a multi-day rally of consecutive record closing highs as profit-taking and worries over ongoing inflation fueled a broad sell-off.\nAll three major U.S. stock indexes lost ground, marking the conclusion of an eight-session streak of all-time closing highs set by the S&P 500 and the Nasdaq.\nAfter such a run, and in the absence of market-moving catalysts, market participants appeared primed to take profits.\n\"We've had an incredible run, so letting some air out of the balloon is perfectly normal,\" said Ryan Detrick, chief market strategist at LPL Financial in Charlotte, North Carolina.\n\"It's a reminder that stocks can’t go up every day,\" Detrick added. \"We’re seeing some oversold weakness today, nothing overly concerning.\"\nThe Labor Department's producer prices (PPI) report showed inflation continues to gather heat as ongoing goods and labor supply challenges send price growth further beyond the U.S. Federal Reserve's average annual 2% inflation target.\nWednesday's CPI report will be scrutinized for clues regarding the extent to which producer prices are being passed along to the consumer, whose spending represents about 70% of the U.S. economy.\nThe Dow Jones Industrial Average(.DJI)fell 112.24 points, or 0.31%, to 36,319.98, the S&P 500(.SPX)lost 16.45 points, or 0.35%, to 4,685.25 and the Nasdaq Composite(.IXIC)dropped 95.81 points, or 0.6%, to 15,886.54.\nFive of the 11 major sectors of the S&P 500 ended the session red, with consumer discretionary(.SPLRCD)shedding 1.4%, the largest percentage drop. Utilities(.SPLRCU)led the gainers, advancing 0.4%.\nThe finish line for third-quarter earnings season is in sight, with 445 of the companies in the S&P 500 having reported. Of those, 81% have beat consensus, according to Refinitiv.\nGeneral Electric Co(GE.N)surged 2.6% following the 129-year-old industrial conglomerate's announcement that it would split into three separate public companies to simplify its business.read more\nTesla Inc(TSLA.O)plunged 12.0%, weighing on the consumer discretionary sector(.SPLRCD)and extending its losses after Chief Executive Elon Musk's Twitter poll proposing to sell a tenth of his holdings garnered a 57.9% vote in favor of the sale. This raised questions as to whether Musk violated a settlement with the U.S. Securities and Exchange Commission (SEC).read more\nOnline retail stock-trading app Robinhood Markets Inc(HOOD.O)reported a security breach affecting about 5 million customers, sending its shares sliding dropped 3.4%.read more\nOn the plus side, upbeat quarterly results sent video game maker Zynga Inc(ZNGA.O)jumping 9.4% and shares of homebuilder D.R. Horton(DHI.N)up 5.2%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.13-to-1 ratio; on Nasdaq, a 1.40-to-1 ratio favored decliners.\nThe S&P 500 posted 34 new 52-week highs and two new lows; the Nasdaq Composite recorded 120 new highs and 73 new lows.\nVolume on U.S. exchanges was 11.02 billion shares, compared with the 10.76 billion average over the last 20 trading days.\nNIO Inc. Reports Unaudited Third Quarter 2021 Financial Results\nNIO Inc. (NIO) reported mixed financial results for Q3 FY 2021. The company posted a loss per share of RMB 1.82 ($0.28), more than twice as large as the loss per share analysts expected. Revenue, however, beat expectations, rising 116.6% year over year (YOY). NIO's vehicle deliveries, which were reported at the beginning of October, exceeded analysts' forecasts. The company's shares fell more than 2% in post-market trading. Over the past year, NIO's shares have provided a total return of -7.7%, well below the S&P 500's total return of 32.0%.\nCoinbase Stock Sinks 10% Following Q3 Revenue Miss, Analyst Highlights Worsening Take Rate\nCoinbase (NASDAQ: COIN) shares were trading more than 10% lower after-hours, following the company’s Q3 results, with revenue coming in at $1.31 billion ($1.1 billion in transaction revenue and $145 million in Subscription and services revenue), below the consensus estimate of $1.56 billion. Quarterly EPS of $1.62 was better than the consensus estimate of $1.57. Verified Users grew to 73 million in Q3 and retail Monthly Transacting Users (MTUs) were 7.4 million.\nDoorDash Stock Rips Higher on Earnings, Plan to Acquire Wolt for ~$8B\nDoorDash, Inc. (NYSE: DASH) shares surged 12% after hours Tuesday following earnings and news the company will acquire Finland-based Wolt Enterprises OY, a leading local commerce platform across 23 countries, in an all-stock transaction valued approximately at €7 billion (U.S. $8.09 billion).\nUpstart Stock Plunges 22% Despite Q3 Beat\nUpstart Holdings (NASDAQ: UPST) shares were trading around 22% lower after-hours, despite the company’s reported Q3 beat, with EPS coming in at $0.60, better than the consensus estimate of $0.35. Quarterly revenue grew 250% to $228.5 million, beating the consensus estimate of $214.9 million.\nSports-Focused Streamer FuboTV Smashes Subscriber Goal In Third Quarter\nFuboTV lost 74 cents a share on sales of $156.7 million in the third quarter. Wall Street had predicted a loss of 61 cents a share on revenue of $143.5 million, FactSet said.On an adjusted basis, FuboTV lost 59 cents a share, compared with a loss of $1.08 a share in the year-earlier period.\nUnity Software Beats Third-Quarter Targets, Buys Weta Digital\nVideo game design and animation software makerUnity Software late Tuesday crushed Wall Street's sales target for the third quarter and reported a smaller loss than expected. Unity stock was in record high territory ahead of the earnings report.\nThe San Francisco-based company lost an adjusted 6 cents a share on sales of $286.3 million in the September quarter. Analysts expected Unity to lose 7 cents a share on sales of $266.5 million, according to FactSet. In the year-earlier period, Unity lost 9 cents a share on sales of $200.8 million.\nPubMatic Announces Third Quarter 2021 Financial Results\nRevenue in the third quarter of 2021 was $58.1 million, an increase of 54% over $37.8 million in the same period of 2020; GAAP net income was $13.5 million, or $0.24 per diluted share in the third quarter, an increase over net income of $6.2 million, or $0.10 per diluted share in the same period of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600939962,"gmtCreate":1638029748530,"gmtModify":1638029748620,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"v","listText":"v","text":"v","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600939962","repostId":"2186389343","repostType":4,"repost":{"id":"2186389343","pubTimestamp":1637974214,"share":"https://www.laohu8.com/m/news/2186389343?lang=&edition=full","pubTime":"2021-11-27 08:50","market":"us","language":"en","title":"2 Leading Growth Stocks to Buy in 2021 and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2186389343","media":"Motley Fool","summary":"These two stocks could be ready to soar next year.","content":"<p>Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that could be the market darlings of 2022 and beyond.</p>\n<p>Two trends that will surely lead to big returns are the emerging digital economy and demand for computer peripherals from the growing adoption of remote work. Here's why <b>Logitech International</b> (NASDAQ:LOGI) and <b>Coinbase Global</b> (NASDAQ:COIN) are well positioned to tackle these opportunities and deliver major gains for investors.</p>\n<h2>Logitech: A leading brand of computer peripherals</h2>\n<p>Logitech has seen growing demand in recent years from a few different trends. One is the increasing popularity of gaming, particularly esports. CEO Bracken Darrell previously said, \"Gaming will grow to become the biggest collection of sports in the world one day from both a participant and a spectator standpoint.\" The company is also benefiting as more businesses shift to a hybrid workforce, allowing employees to split time between working at home or at the office. Both opportunities are boosting sales of Logitech's mice, keyboards, webcams, and headsets.</p>\n<p>The share price has fallen this year as a result of difficult year-over-year comparisons with calendar 2020 when the stay-at-home environment drove sales through the roof.&nbsp;However, the gaming peripherals market is expected to roughly double in size to $8.7 billion by 2027, according to Research and Markets.&nbsp;That's a strong tailwind for Logitech's gaming business, which generated revenue of $1.4 billion over the last four quarters.</p>\n<p>The number of remote workers is also expected to continue increasing over the next few years. <b>Gartner</b> estimates 53% of the U.S. workforce will be working remotely in 2022&nbsp;with similar trends across Europe, India, and China.</p>\n<p>Logitech is gaining market share across most of its product categories, but supply chain challenges could pressure near-term growth. The tough growth comparisons with last year and the near-term headwinds are giving investors a great opportunity to buy the stock at a forward price-to-earnings multiple of 18.4.&nbsp;These valuation levels should lay the foundation for market-beating returns.</p>\n<h2>Coinbase: A leading cryptocurrency exchange</h2>\n<p>Coinbase is one of the largest exchanges for buying and selling cryptocurrency. It has over 73 million verified users across more than 100 countries. It is popular for its easy-to-use interface that includes helpful educational features to help new users get up to speed on the burgeoning cryptoeconomy, but it may win over millions more users as the digital economy goes mainstream.</p>\n<p>The stock started trading in April through a direct listing and is currently down 18% from its opening price on April 14, but it's probably only a matter of time until shares bounce back. The company is growing very fast with assets on the platform rising from $36 billion in the third quarter of 2020 to $255 billion in the same period this year. The surge in demand pushed net profit up to $406 million in the latest quarter.</p>\n<p>Investors should keep in mind management is not interested in maximizing profits right now, instead focusing on investments in new products and services to attract more users to the platform. Profits could decline during periods of soft trading volume, but Coinbase should continue to see an upward trend for its user base over the next several years, and that's the most important progress to think about.</p>\n<p>It's estimated that up to 200 million people have used <b>Bitcoin</b>,&nbsp;but with the most popular cryptocurrency still gaining adoption worldwide, especially in developing countries, the number of people using it could reach one billion in the next five years, according to some analysts. This makes Coinbase's 7.4 million monthly transacting users look minuscule by comparison.</p>\n<p>The opportunity is clear, but Coinbase currently trades at a relatively modest price-to-earnings ratio of 28 for a growth stock, which could look very cheap in another 10 years.&nbsp;This is one of the top cryptocurrency stocks to consider in this booming market.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Leading Growth Stocks to Buy in 2021 and Beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Leading Growth Stocks to Buy in 2021 and Beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-27 08:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LOGI":"罗技","COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/11/26/2-leading-growth-stocks-to-buy-in-2021-and-beyond/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186389343","content_text":"Valuations for many growth stocks are getting expensive, which could limit returns in the near term. But if you know where to look, there are some hidden gems trading at reasonable valuations that could be the market darlings of 2022 and beyond.\nTwo trends that will surely lead to big returns are the emerging digital economy and demand for computer peripherals from the growing adoption of remote work. Here's why Logitech International (NASDAQ:LOGI) and Coinbase Global (NASDAQ:COIN) are well positioned to tackle these opportunities and deliver major gains for investors.\nLogitech: A leading brand of computer peripherals\nLogitech has seen growing demand in recent years from a few different trends. One is the increasing popularity of gaming, particularly esports. CEO Bracken Darrell previously said, \"Gaming will grow to become the biggest collection of sports in the world one day from both a participant and a spectator standpoint.\" The company is also benefiting as more businesses shift to a hybrid workforce, allowing employees to split time between working at home or at the office. Both opportunities are boosting sales of Logitech's mice, keyboards, webcams, and headsets.\nThe share price has fallen this year as a result of difficult year-over-year comparisons with calendar 2020 when the stay-at-home environment drove sales through the roof. However, the gaming peripherals market is expected to roughly double in size to $8.7 billion by 2027, according to Research and Markets. That's a strong tailwind for Logitech's gaming business, which generated revenue of $1.4 billion over the last four quarters.\nThe number of remote workers is also expected to continue increasing over the next few years. Gartner estimates 53% of the U.S. workforce will be working remotely in 2022 with similar trends across Europe, India, and China.\nLogitech is gaining market share across most of its product categories, but supply chain challenges could pressure near-term growth. The tough growth comparisons with last year and the near-term headwinds are giving investors a great opportunity to buy the stock at a forward price-to-earnings multiple of 18.4. These valuation levels should lay the foundation for market-beating returns.\nCoinbase: A leading cryptocurrency exchange\nCoinbase is one of the largest exchanges for buying and selling cryptocurrency. It has over 73 million verified users across more than 100 countries. It is popular for its easy-to-use interface that includes helpful educational features to help new users get up to speed on the burgeoning cryptoeconomy, but it may win over millions more users as the digital economy goes mainstream.\nThe stock started trading in April through a direct listing and is currently down 18% from its opening price on April 14, but it's probably only a matter of time until shares bounce back. The company is growing very fast with assets on the platform rising from $36 billion in the third quarter of 2020 to $255 billion in the same period this year. The surge in demand pushed net profit up to $406 million in the latest quarter.\nInvestors should keep in mind management is not interested in maximizing profits right now, instead focusing on investments in new products and services to attract more users to the platform. Profits could decline during periods of soft trading volume, but Coinbase should continue to see an upward trend for its user base over the next several years, and that's the most important progress to think about.\nIt's estimated that up to 200 million people have used Bitcoin, but with the most popular cryptocurrency still gaining adoption worldwide, especially in developing countries, the number of people using it could reach one billion in the next five years, according to some analysts. This makes Coinbase's 7.4 million monthly transacting users look minuscule by comparison.\nThe opportunity is clear, but Coinbase currently trades at a relatively modest price-to-earnings ratio of 28 for a growth stock, which could look very cheap in another 10 years. This is one of the top cryptocurrency stocks to consider in this booming market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}